The Bing Center for Waldenström's Macroglobulinemia (WM) is the largest center in the world dedicated to the study and development of new, targeted treatments for WM and related Immunoglobulin M (IgM) disorders, including IgM-related neuropathy and Bing Neel syndrome. The Center is credited with the approval of the first-ever drug for WM (ibrutinib), the advancement of many new drugs for WM through clinical trials, and the discovery of the MYD88 and CXCR4 mutations which are critical in WM.
The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:
- Evaluations and ongoing clinical care
- Consultations (second opinions)
- Genomic testing for relevant mutations including MYD88, CXCR4, and TP53
- Pathology review of biopsy samples
- A personalized treatment plan offering the latest therapies
- Access to clinical trials offering novel treatments
- Participation in research studies of WM genomics and new drug discovery
- Complementary therapies through the Leonard P. Zakim Center for Integrative Therapies and Healthy Living
